Calming an overactive immune system with special cells
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have hard-to-treat rheumatoid arthritis or severe scleroderma with skin and lung involvement.
- Your disease is still active despite trying other treatments.
- You do not have any other major health conditions or infections like hepatitis or HIV.
- You have not had a previous cell therapy or certain other experimental treatments.
- You are willing to use effective birth control and to be followed for 15 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
This trial tests a new type of 'universal' CAR-T cell therapy (made from donor cells) combined with immune-suppressing drugs for people with severe autoimmune diseases that haven't responded to standard treatments. The goal is to see if this approach can control the immune system and reduce disease activity.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.